Xlife Sciences AG: Exit of a project company
Xlife Sciences AG / Key word(s): Investment Xlife Sciences AG: Exit of a project company More than 20 million euros transaction completed Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates. About Veraxa Biotech AG About Xlife Sciences AG
23-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Xlife Sciences AG |
Klausstrasse 19 | |
8008 Zürich | |
Switzerland | |
Phone: | 0041 44 385 84 60 |
E-mail: | info@xlifesciences.ch |
Internet: | www.xlifesciences.ch |
ISIN: | CH0461929603 |
WKN: | A2PK6Z |
Listed: | Regulated Unofficial Market in Frankfurt, Munich |
EQS News ID: | 1157122 |
End of Announcement | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website: